SCHEMBL5362344

SCHEMBL5362344

Nc1ncnc2c1nc(O)n2[C@@H]1O[C@H](CO)C(O)C1O

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSPA8 P11142 5/20 0.80
HSPA5 P11021 2/20 0.80
RXFP1 Q9HBX9 1/20 0.72
GAPDH P04406 3/20 0.69
HSD17B10 Q99714 1/20 0.69
SMN1; SMN2 Q16637 2/20 0.68
LMNA P02545 1/20 0.68
TP53 P04637 1/20 0.68
HBB P68871 1/20 0.68
ADORA3 P0DMS8 3/20 0.64
SLC28A2 O43868 4/20 0.63
DPP4 P27487 1/20 0.63
MEN1 O00255 1/20 0.63
SLC28A1 O00337 1/20 0.63
MAP3K7 O43318 1/20 0.63
MAPK1 P28482 1/20 0.63
ADORA2A P29274 1/20 0.63
ADORA2B P29275 1/20 0.63
ADORA1 P30542 1/20 0.63
STAT6 P42226 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6305168 1.00 HSPA8 (0.80) HSPA8HSPA5RXFP1GAPDHHSD17B10
SCHEMBL1145052 0.89 HSPA8 (1.00) HSPA8HSPA5RXFP1GAPDHHSD17B10
SCHEMBL1145049 0.89 HSPA8 (1.00) HSPA8HSPA5RXFP1GAPDHHSD17B10
SCHEMBL17412455 0.89 HSPA8 (1.00) HSPA8HSPA5RXFP1GAPDHHSD17B10
SCHEMBL4126993 0.88 HSPA8 (0.80) HSPA8HSPA5RXFP1GAPDHHSD17B10
SCHEMBL1135195 0.88 HSPA8 (0.80) HSPA8HSPA5RXFP1GAPDHHSD17B10
SCHEMBL15906323 0.88 HSPA8 (0.80) HSPA8HSPA5RXFP1GAPDHHSD17B10
SCHEMBL18858928 0.88 HSPA8 (0.80) HSPA8HSPA5RXFP1GAPDHHSD17B10
SCHEMBL967124 0.88 HSPA8 (0.80) HSPA8HSPA5RXFP1GAPDHHSD17B10
SCHEMBL15906300 0.88 HSPA8 (0.80) HSPA8HSPA5RXFP1GAPDHHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180140694-A1 DOSAGE REGIMEN FOR HIV VACCINE BIONOR IMMUNO AS (NO) 2018-05-24 US claimed
WO-2016177833-A1 DOSAGE REGIMEN FOR HIV VACCINE BIONOR IMMUNO AS (NO) 2016-11-10 WO claimed
US-6900291-B2 Detection and quantitation of 8-OH-adenine using monoclonal antibodies CYTOCHEM, INC. (US) 2005-05-31 US claimed
EP-4746905-A1 RSV VACCINE Astrazeneca AB (SE) 2026-05-27 EP disclosed
WO-2026104647-A1 VACCINE ASTRAZENECA AB (SE) 2026-05-21 WO disclosed
WO-2025125630-A1 METHOD FOR BIOPROTAC DESIGN MEDIMMUNE LIMITED (GB) 2025-06-19 WO disclosed
US-20250041400-A1 RSV VACCINE ASTRAZENECA PHARMACEUTICALS LP 2025-02-06 US disclosed
WO-2025017142-A1 RSV VACCINE ASTRAZENECA AB (SE) 2025-01-23 WO disclosed
WO-2024151994-A1 MONOCLONAL ANTIBODIES THAT RECOGNIZE 8-OXO-ADENINE IN NUCLEIC ACIDS AND THEIR USE IN DIAGNOSTIC AND QUALITY CONTROL ASSAYS CYMBA X, LLC (US) 2024-07-18 WO disclosed
US-11976296-B2 Means and methods for generating midbrain organoids UNIVERSITÉ DU LUXEMBOURG (LU) 2024-05-07 US disclosed
US-20240009114-A1 COMPOSITION FOR MICRONEEDLE ADMINISTRATION AND IT'S APPLICATIONS Zcapsule Pharmaceuticals Co., Ltd. (CN) 2024-01-11 US disclosed
WO-2016177833-A1 DOSAGE REGIMEN FOR HIV VACCINE BIONOR IMMUNO AS (NO) 2016-11-10 WO disclosed
WO-2014128289-A1 BIOMEDICAL DEVICE IMPLANTABLE IN BONE AND/OR CARTILAGINOUS TISSUE, AND CORRESPONDING METHOD TO MANUFACTURE SAID BIOMEDICAL DEVICE LUMETTI, SIMONE (IT) 2014-08-28 WO disclosed
CN-103502450-A Methods and materials for nucleic acid manipulation BASF SE 2014-01-08 CN disclosed
US-20120295311-A1 Methods and Materials for Nucleic Acid Manipulation BASF SE (DE) 2012-11-22 US disclosed
US-7244572-B1 One-dimensional arrays on optical fibers WISYS TECHNOLOGY FOUNDATION, INC. (US) 2007-07-17 US disclosed
US-6900291-B2 Detection and quantitation of 8-OH-adenine using monoclonal antibodies CYTOCHEM, INC. (US) 2005-05-31 US disclosed
US-20030186344-A1 Detection and quantitation of 8-OH-adenine using monoclonal antibodies CYTOCHEM, INC. 2003-10-02 US disclosed
US-6187551-B1 HYBRIDOMA CULTURE PRODUCT CYTOCHEM, INC. 2001-02-13 US disclosed
WO-1997011371-A1 DETECTION AND QUANTITATION OF 8-OH-ADENINE USING MONOCLONAL ANTIBODIES CYTOCHEM, INC. (US) 1997-03-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250041400-A1 RSV VACCINE LSS, SLFN12, FDPS HSPA8 1320/4885HSPA5 2660/4885RXFP1 2851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.